Selexis CHO Cells in Suspension-1

WEBINAR:Harnessing Whole Genome Sequencing and FISH Analysis for Authentication of Monoclonality of CHO Cell Lines

January 2021

Pierre-Olivier Duroy, PhD, Director Emerging Technologies

Establishing monoclonality of research cell banks (RCB) and master cell banks (MCB) is critical for successful and cost-effective biologic manufacturing campaigns and regulatory filings. Using whole genome sequencing (WGS) and proprietary bioinformatics tools, Selexis is able to establish monoclonality through an unbiased approach that identifies and validates integration sites, establishes clonality using integration sites as markers and provide transgene sequence, copy number and integrity.

WATCH WEBINAR

Ready To Learn More?

Access the Webinar!

 
Selexis CHO cells high expressing mAB bispecific antibody
 

Driven by Excellence. Guided by Science.


Connect with us.
From ubiquitous immunoglobulin-based drugs such as monoclonal and bispecific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice

 

 

Connect with Us

 

Explore the SUREtechnology Platform™

Selexis Monoclonal Antibodies block

Monoclonal Antibodies

For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.

Learn More
Selexis Difficult-to-Express Proteins block

Difficult-to-Express Proteins

At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.

Learn More
Selexis Bispecific Antibodies block

Bispecific Antibodies

We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.

Learn More
Selexis SA footer Logo

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

 

A JSR Life Sciences Company Logo
EN-BEST MEDIUM WORKPLACES_CMYK

Latest News

April 17, 2023

KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO

Read More
March 21, 2023

KBI Releases Inaugural FIH Batch at Geneva Five Months After Opening

Read More

Copyright© 2023 Selexis SA. All Rights Reserved.